Effect of radioiodination on the binding of monoclonal antibody DF3 to breast carcinoma cells.

Journal Article (Journal Article)

The murine monoclonal antibody (MAb) designated DF3 is an IgG1 prepared against a membrane enriched fraction of human breast carcinoma. MAb DF3 reacts with a family of large molecular weight glycoproteins expressed by 78% of breast cancer cells and 95% of epithelial ovarian cancer cells. Binding to the breast cancer cell line, MCF-7, of native MAb DF3 was compared to that of MAb DF3 exposed to different concentrations of Iodogen or Bolton-Hunter reagent. The amount of MAb DF3 required to obtain half-maximal binding (B1/2max) with MCF-7 extract for native MAb DF3 IgG was 180 ng, while the B1/2max for MAb DF3 IgG exposed to 1 and 10 micrograms Iodogen was 580 ng and 1800 mg, respectively. In contrast, the B1/2max for MAb DF3 IgG treated with Bolton-Hunter reagent was not different from that for native MAb DF3 IgG. Similar results were obtained with F(ab')2. Immunoreactive fractions for the 125I-labeled MAb DF3 were 0.13, 0.24 and 0.65 for IgG after exposure to 1 microgram Iodogen, 10 micrograms Iodogen and Bolton-Hunter, respectively. Immunoreactive fractions for F(ab')2 were 0.08, 0.08, and 0.53 for 1 and 10 micrograms Iodogen and Bolton-Hunter reagent, respectively. Association constants (Ka) were significantly higher for MAb DF3 IgG radioiodinated with Bolton-Hunter (3.97 +/- 0.38 x 10(8) M-1) than for IgG exposed to 1 microgram Iodogen (2.78 +/- 0.30 x 10(8) M-1) or 10 micrograms Iodogen (1.03 +/- 0.12 x 10(8) M-1). Similarly, the Ka ratio observed for the F(ab')2 radioiodinated with Bolton-Hunter reagent, 1 or 10 micrograms Iodogen was 22 to 3 to 1.(ABSTRACT TRUNCATED AT 250 WORDS)

Full Text

Duke Authors

Cited Authors

  • Hayes, DF; Noska, MA; Kufe, DW; Zalutsky, MR

Published Date

  • 1988

Published In

Volume / Issue

  • 15 / 3

Start / End Page

  • 235 - 241

PubMed ID

  • 2454899

International Standard Serial Number (ISSN)

  • 0883-2897

Digital Object Identifier (DOI)

  • 10.1016/0883-2897(88)90101-8


  • eng

Conference Location

  • England